Traders cheer after the company completes its merger agreement. Here's what investors need to know.
News & Analysis: Keryx Biopharmaceuticals
The pharma company announced second-quarter 2018 earnings.
Shares of both companies tumble after the two entities announced the signing of a merger agreement. Here's what investors need to know.
Shares took a nosedive after the company's earnings report, but with a new FDA approval under its belt, this could be a buying opportunity for investors.
The company's winning new customers, but that didn't help its third-quarter financials.
It was another down month for the small-cap biopharma, but this pending regulatory news promises to turn the company's fortunes around.
One in four of the company's shares is currently being shorted, but bears appear to be wrong about this pharma stock.
Flexion Therapeutics, Keryx, and Zogenix have market-moving news on deck that could cause shares to soar or plummet in the next few months.
Zogenix, Insys Therapeutics, and Keryx Pharmaceuticals shares have been gaining back some of their losses in 2017 -- are they worth buying now?
Sales are finding their footing at this biotech, and optimism is increasing ahead of an important FDA decision later this year.